UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Heartflow, Inc. (NASDAQ:HTFL – Free Report) by 3.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,465,650 shares of the company’s stock after buying an additional 50,822 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Heartflow were worth $43,002,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. purchased a new stake in shares of Heartflow in the third quarter valued at $48,871,000. Legal & General Group Plc purchased a new position in shares of Heartflow during the 3rd quarter worth about $59,000. Franklin Resources Inc. bought a new position in Heartflow during the 3rd quarter valued at about $10,829,000. UBS Group AG purchased a new stake in Heartflow in the 3rd quarter worth about $5,130,000. Finally, Sei Investments Co. bought a new stake in Heartflow in the third quarter worth about $303,000.
Insider Activity
In other Heartflow news, insider Campbell Rogers sold 9,219 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $41.23, for a total transaction of $380,099.37. Following the transaction, the insider owned 86,459 shares of the company’s stock, valued at approximately $3,564,704.57. This trade represents a 9.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Farquhar sold 38,900 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the completion of the sale, the chief executive officer owned 457,935 shares of the company’s stock, valued at approximately $16,027,725. This represents a 7.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 191,271 shares of company stock worth $7,089,136. 7.70% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Read Our Latest Report on HTFL
Heartflow Stock Performance
Heartflow stock opened at $49.71 on Friday. The company has a market capitalization of $4.32 billion and a PE ratio of -27.16. The company has a 50 day moving average price of $33.50 and a 200-day moving average price of $29.79. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $51.78.
Heartflow (NASDAQ:HTFL – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million for the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The business’s quarterly revenue was up 47.7% on a year-over-year basis. On average, analysts forecast that Heartflow, Inc. will post -0.75 earnings per share for the current year.
Heartflow Profile
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Further Reading
- Five stocks we like better than Heartflow
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Want to see what other hedge funds are holding HTFL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heartflow, Inc. (NASDAQ:HTFL – Free Report).
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
